Biyun Y. Wang

270 Dong An Road
Shanghai, 200032, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 129 publications

Prominin 2 promotes the progression of breast cancer by inhibiting ferroptosis via MAPK signaling.

Prominin 2 promotes the progression of breast cancer by inhibiting ferroptosis via MAPK signaling.

Journal: Journal of translational internal medicine

Published: August 27, 2026

Clinical impact of 18F-FES PET/CT-detected ER-positive conversion in metastatic breast cancer with ER-negative primary tumors.

Clinical impact of 18F-FES PET/CT-detected ER-positive conversion in metastatic breast cancer with ER-negative primary tumors.

Journal: European journal of nuclear medicine and molecular imaging

Published: May 06, 2026

Bireociclib Plus Fulvestrant in Advanced Breast Cancer After Endocrine Progression: The BRIGHT-2 Phase 3 Randomized Clinical Trial.

Bireociclib Plus Fulvestrant in Advanced Breast Cancer After Endocrine Progression: The BRIGHT-2 Phase 3 Randomized Clinical Trial.

Journal: JAMA oncology

Published: March 19, 2026

Phase II Clinical Study of Adebrelimab and Bevacizumab Combined With Cisplatin/Carboplatin in Patients With Triple-Negative Breast Cancer With Brain Metastases (ABC Study).

Phase II Clinical Study of Adebrelimab and Bevacizumab Combined With Cisplatin/Carboplatin in Patients With Triple-Negative Breast Cancer With Brain Metastases (ABC Study).

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: March 04, 2026

Expert consensus on the detection and clinical application of tumor mutational burden.

Expert consensus on the detection and clinical application of tumor mutational burden.

Journal: Cancer biology & medicine

Published: February 18, 2026

Trastuzumab rezetecan versus pyrotinib plus capecitabine for patients with HER2-positive metastatic breast cancer (HORIZON-Breast01): interim analysis of a multicentre, open-label, randomised, controlled, phase 3 trial.

Trastuzumab rezetecan versus pyrotinib plus capecitabine for patients with HER2-positive metastatic breast cancer (HORIZON-Breast01): interim analysis of a multicentre, open-label, randomised, controlled, phase 3 trial.

Journal: The Lancet. Oncology

Published: November 14, 2025

Targeted GLP-1 nanotherapy for Wnt/β-catenin activation to enhance endothelial progenitor cell-mediated re-endothelialization and prevent intracranial aneurysm recurrence.

Targeted GLP-1 nanotherapy for Wnt/β-catenin activation to enhance endothelial progenitor cell-mediated re-endothelialization and prevent intracranial aneurysm recurrence.

Journal: Journal of neurosurgery

Published: September 10, 2025

A phase II randomized trial of gemcitabine plus cisplatin (GP) versus gemcitabine plus carboplatin (GC) as the first-line treatment of patients with metastatic triple-negative breast cancer.

A phase II randomized trial of gemcitabine plus cisplatin (GP) versus gemcitabine plus carboplatin (GC) as the first-line treatment of patients with metastatic triple-negative breast cancer.

Journal: ESMO open

Published: August 27, 2025

Chinese Society of Clinical Oncology breast cancer expert consensus on the diagnosis and treatment of breast cancer brain metastasis (2025).

Chinese Society of Clinical Oncology breast cancer expert consensus on the diagnosis and treatment of breast cancer brain metastasis (2025).

Journal: Translational breast cancer research : a journal focusing on translational research in breast cancer

Published: August 12, 2025

Real-world application of 18F-FES PET/CT on HR + breast cancer patients with brain metastases.

Real-world application of 18F-FES PET/CT on HR + breast cancer patients with brain metastases.

Journal: European journal of nuclear medicine and molecular imaging

Published: August 07, 2025

Efficacy and safety of ARX788 for individuals with HER2-positive breast cancer and brain metastases (ACE-Breast-06): a single-arm, phase 2 trial in China.

Efficacy and safety of ARX788 for individuals with HER2-positive breast cancer and brain metastases (ACE-Breast-06): a single-arm, phase 2 trial in China.

Journal: EClinicalMedicine

Published: July 31, 2025

Clinical and genomic characteristics of HER2-ultralow breast cancer and implications for T-DXd therapy.

Clinical and genomic characteristics of HER2-ultralow breast cancer and implications for T-DXd therapy.

Journal: Precision clinical medicine

Published: July 19, 2025

Showing 1-12 of 129

Last Updated: 09/26/2026